<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346943</url>
  </required_header>
  <id_info>
    <org_study_id>ALTURA-FIM-1</org_study_id>
    <nct_id>NCT01346943</nct_id>
  </id_info>
  <brief_title>The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study</brief_title>
  <official_title>The Altura AAA Endograft Safety and Feasibility Study For Exclusion of Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altura Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altura Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of deploying and implanting the Altura
      Abdominal Aortic Aneurysm (AAA) Endograft in the treatment of abdominal aortic aneurysms in
      subjects who are candidates for open surgical aneurysm repair.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of major adverse events.</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events defined as the composite endpoint of death, significant blood loss requiring intervention, respiratory failure, myocardial infarction, renal failure, paralysis, stroke, bowel ischemia and/or device migration causing vascular compromise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of device defined by clinical and technical success</measure>
    <time_frame>6 months, 1 year and 2 years</time_frame>
    <description>Evaluate the feasibility of using Altura AAA Endograft. Feasibility is comprised of acute clinical and technical success measured at the time of procedure. Long-term safety will be evaluated at 6 months, 1 year and 2 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>AAA Stent Graft System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Altura Medical AAA Stent Graft System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Altura Medical Abdominal Aortic Aneurysm Stent-Graft</intervention_name>
    <description>Altura Medical AAA Stent Graft System</description>
    <arm_group_label>AAA Stent Graft System</arm_group_label>
    <other_name>Altura Medical AAA Stent Graft System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Subject or subject's legal representative understands and has signed an informed
             consent.

          -  Infrarenal aneurysmal neck diameter between 18 and 28mm, inclusive.

          -  Abdominal aneurysm neck angulation &lt; 45 degrees.

          -  Infrarenal non-aneurysmal neck &gt;/= 15mm in length.

          -  Abdominal aneurysm &gt;4.5cm and growth &gt;1.0 cm/yr.

          -  Limited iliac artery tortuosity.

          -  Iliac artery fixation length of &gt;/= 15mm.

          -  Iliac artery diameter between 8 and 19 mm, inclusive.

          -  Iliac artery diameter accessible by a 14 Fr introducer.

          -  Subject is a candidate for open surgical repair of abdominal aortic aneurysm.

          -  Patent iliac or femoral arteries access vessels, size and morphology to allow
             endovascular access of 14 Fr introducer sheaths and catheters.

          -  Subject has &gt; one year life expectancy.

          -  Subject is not placed at additional risk while waiting for additional imaging
             necessary for vascular treatment.

          -  Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive.

          -  Subject is able and willing to comply with 30 day, six (6) month, one (1) year and 2
             (two) year follow-up.

        Exclusion Criteria:

          -  Subject has an acutely ruptured or leaking or emergent aneurysm.

          -  Subject has a dissecting aneurysm.

          -  Subject has a mycotic or infected aneurysm.

          -  Subject has current vascular injury due to trauma.

          -  Subject's aneurysm is thoracic or suprarenal.

          -  Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.

          -  Subject has thrombus, calcification and/or plaque that may compromise sealing

          -  Subject has had a myocardial infarction within six (6) months prior to enrollment.

          -  Subject has current angina or other active cardiac condition such as congestive heart
             failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular
             disease.

          -  Subject has undergone other major surgery within the 30 days prior to enrollment.

          -  Subject is pregnant or nursing.

          -  Known allergy to nitinol or polyester or contrast material that cannot be pretreated.

          -  Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray
             visualization of the aorta.

          -  Subject has connective tissue disease (e.g., Marfan's syndrome).

          -  Subject has a bleeding disorder or anemia defined as hemoglobin &lt; 9.0 mg/dL.

          -  Subject is hypercoagulable.

          -  Subject is on dialysis or has compromised renal function as reflected by a serum
             creatinine &gt;2.2 mg/dL.

          -  Subject has compromised hepatic function as measured by SGPT (ALT) &gt; three (3) times
             the upper limit of normal.

          -  Subject has active systemic infection.

          -  Subject is participating in another research study involving an investigational agent
             for the treatment of AAA.

          -  Subject has other medical, social or psychological problems that, in the opinion of
             the investigator, preclude them from receiving this treatment and the procedures and
             evaluations pre- and post-treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albrecht Kramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica De Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Latvia</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominal Aortic Aneurysms, AAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

